Lorecivivint

DRUG6 trials

Sponsors

Biosplice Therapeutics, Inc.

Conditions

Knee OsteoarthritisOsteoarthritis of the KneeOsteoarthritis, Knee

Phase 2

MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis

TerminatedNCT03706521

Biosplice Therapeutics, Inc.Knee Osteoarthritis

Start: 2019-03-11End: 2020-12-21Updated: 2026-03-04

Phase 3

Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis

CompletedNCT03928184

Biosplice Therapeutics, Inc.Knee Osteoarthritis

Start: 2019-05-17End: 2021-08-20Updated: 2026-02-13

Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)

CompletedNCT04385303

Biosplice Therapeutics, Inc.Knee Osteoarthritis

Start: 2020-05-26End: 2021-09-08Updated: 2026-02-04

A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee

TerminatedNCT04520607

Biosplice Therapeutics, Inc.Osteoarthritis, Knee

Start: 2020-08-25End: 2023-06-30Updated: 2026-03-24

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

TerminatedNCT04931667

Biosplice Therapeutics, Inc.Osteoarthritis of the Knee

Start: 2021-07-15End: 2021-12-13Updated: 2026-03-31

Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis (STRIDES)

CompletedNCT05603754

Biosplice Therapeutics, Inc.Knee Osteoarthritis

Start: 2022-11-18End: 2024-02-20Updated: 2026-09-01

Related Papers

Impact of structural severity on outcomes in knee osteoarthritis: an analysis of data from phase 2 and phase 3 lorecivivint clinical trials.

2025-05-016 citations